UCB (OTCMKTS:UCBJF) Shares Gap Up – Here’s Why

UCB SA (OTCMKTS:UCBJF)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $284.00, but opened at $300.00. UCB shares last traded at $304.99, with a volume of 10,593 shares traded.

Wall Street Analyst Weigh In

A number of research firms have recently commented on UCBJF. Barclays reaffirmed an “overweight” rating on shares of UCB in a research note on Tuesday, January 6th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research report on Monday, February 16th. Wolfe Research initiated coverage on UCB in a report on Monday, February 23rd. They issued an “outperform” rating for the company. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of UCB in a research note on Monday, December 8th. Finally, Stephens reiterated an “overweight” rating on shares of UCB in a research note on Thursday, January 15th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy”.

UCB Trading Up 7.4%

The stock’s 50 day simple moving average is $311.98 and its 200-day simple moving average is $286.73. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

About UCB

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.